Diagnostic Test Accuracy Protocol

You have free access to this content

Biomarkers for assessing disease activity in inflammatory bowel disease

  1. Mahmoud Mosli1,2,
  2. Marianne Fahmy3,
  3. Sushil K Garg4,
  4. Sean G Feagan5,
  5. Kenneth A Baker5,
  6. GY Zou5,
  7. John K MacDonald5,
  8. William J Sandborn3,
  9. Nilesh Chande6,*

Editorial Group: Cochrane IBD Group

Published Online: 25 NOV 2013

DOI: 10.1002/14651858.CD010848


How to Cite

Mosli M, Fahmy M, Garg SK, Feagan SG, Baker KA, Zou GY, MacDonald JK, Sandborn WJ, Chande N. Biomarkers for assessing disease activity in inflammatory bowel disease (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 11. Art. No.: CD010848. DOI: 10.1002/14651858.CD010848.

Author Information

  1. 1

    London Health Sciences Centre, Victoria Hospital, London, Ontario, Canada

  2. 2

    King Abdulaziz University, King Abdulaziz University Hospital, Jeddah, Saudi Arabia

  3. 3

    University of California San Diego, La Jolla, CA, USA

  4. 4

    University of Minnesota, Department of Surgery, Minneapolis, MN, USA

  5. 5

    Robarts Research Institute, Robarts Clinical Trials, London, Ontario, Canada

  6. 6

    London Health Sciences Centre - Victoria Hospital, London, Ontario, Canada

*Nilesh Chande, London Health Sciences Centre - Victoria Hospital, Room E1-423A, 800 Commissioners Road East, London, Ontario, N6A 5W9, Canada. nchande2@uwo.ca.

Publication History

  1. Publication Status: New
  2. Published Online: 25 NOV 2013

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

The primary objective is to determine the diagnostic accuracy of three commonly studied biomarkers (serum CRP, FC and SL) for assessing disease activity in patients with established IBD (i.e. UC or CD) presenting with symptoms suggestive of active disease.

A secondary objective is to investigate sources of heterogeneity by disease type (i.e. UC or CD), disease severity (e.g. mild, moderate or severe disease), disease location (e.g. distal or proximal involvement) and age.